AbbVie has announced positive topline results from a Phase 3 clinical trial evaluating onabotulinumtoxinA (Botox Cosmetic) for the treatment of moderate to severe platysma prominence in adults. The study met its primary endpoint, demonstrating statistically significant improvements in the aesthetic appearance of vertical neck bands compared to placebo.
Platysma prominence, characterized by visible vertical bands in the neck caused by the platysma muscle, is a common aesthetic concern that becomes more pronounced with aging. The condition can contribute to an aged appearance and is often resistant to non-invasive treatments. Current treatment options have been limited, making this potential new indication for Botox Cosmetic particularly noteworthy for both practitioners and patients seeking neck rejuvenation solutions.
The multicenter, randomized, double-blind, placebo-controlled trial enrolled adults with moderate to severe platysma bands. Participants received injections of either Botox Cosmetic or placebo into the platysma muscle. Investigators assessed treatment outcomes using validated scales measuring the severity of neck band appearance at rest and during muscle contraction. Secondary endpoints included patient satisfaction scores and duration of treatment effect. Safety data collected throughout the study showed a profile consistent with previous Botox Cosmetic trials in other aesthetic indications.
Dr. Michael Kane, a plastic surgeon and aesthetic medicine specialist not involved in the trial, noted that platysma banding represents a significant concern for patients seeking comprehensive facial and neck rejuvenation. “The neck is often overlooked in aesthetic treatments, but it’s one of the first areas to show signs of aging,” he explained. “Having an FDA-approved neuromodulator option specifically for this indication would provide practitioners with an evidence-based treatment protocol.”
AbbVie plans to submit the full study data to the FDA for review as part of a supplemental Biologics License Application. If approved, this would expand the already extensive portfolio of FDA-cleared aesthetic indications for Botox Cosmetic, which currently includes treatment of forehead lines, crow’s feet, and frown lines between the eyebrows. The company expects to present detailed efficacy and safety results at an upcoming medical conference.